Liquidia Stock Earnings Estimates Raised by HC Wainwright

Liquidia Corporation (NASDAQ:LQDA) – Stock analysts at HC Wainwright lifted their FY2028 EPS estimates for shares of Liquidia in a report issued on Thursday, October 15th. HC Wainwright analyst A. Fein now expects that the company will post earnings of $4.94 per share for the year, up from their prior estimate of $4.49. HC Wainwright currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for Liquidia’s current full-year earnings is $2.05 per share. HC Wainwright also issued estimates for Liquidia’s FY2029 earnings at $5.61 EPS and FY2030 earnings at $6.36 EPS.

A number of other research analysts have also recently issued reports on LQDA. Wall Street Zen cut Liquidia from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Citigroup reissued a “neutral” rating on shares of Liquidia in a research note on Thursday, October 1st. Weiss Ratings raised Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. Zacks Research cut Liquidia from a “hold” rating to a “strong sell” rating in a report on Tuesday, September 22nd. Finally, Needham & Company LLC dropped their target price on Liquidia from $72.00 to $58.00 and set a “buy” rating for the company in a report on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $72.85.

Liquidia Stock Performance

Liquidia stock opened at $36.35 on Monday. The firm has a fifty day simple moving average of $57.92 and a two-hundred day simple moving average of $61.69. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. Liquidia has a twelve month low of $21.94 and a twelve month high of $93.61. The company has a market capitalization of $3.25 billion, a PE ratio of 24.91, a P/E/G ratio of 0.30 and a beta of 0.61.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). The business had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. Liquidia’s revenue for the quarter was up 1842.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.49) EPS.

Insider Buying and Selling

In related news, insider Jason Adair sold 73,631 shares of Liquidia stock in a transaction on Friday, August 21st. The shares were sold at an average price of $69.09, for a total value of $5,087,165.79. Following the transaction, the insider directly owned 174,606 shares of the company’s stock, valued at $12,063,528.54. The trade was a 29.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Katherine Rielly-Gauvin sold 36,789 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $74.99, for a total transaction of $2,758,807.11. Following the sale, the director owned 44,637 shares of the company’s stock, valued at $3,347,328.63. This represents a 45.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 666,598 shares of company stock valued at $34,796,390 over the last quarter. Company insiders own 25.60% of the company’s stock.

Institutional Investors Weigh In On Liquidia

A number of large investors have recently added to or reduced their stakes in LQDA. The Manufacturers Life Insurance Company raised its position in Liquidia by 63.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock valued at $2,199,000 after purchasing an additional 22,592 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in Liquidia in the 2nd quarter worth approximately $29,694,000. Seven Fleet Capital Management LP lifted its holdings in Liquidia by 25.2% in the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after buying an additional 51,727 shares during the period. Bank of America Corp DE lifted its holdings in Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after buying an additional 360,372 shares during the period. Finally, Handelsbanken Fonder AB bought a new stake in shares of Liquidia in the 2nd quarter worth approximately $1,993,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler.